News List

Sanofi launches new diabetes management drug Toujeo in India

Toujeo is a once daily, long-acting basal insulin used to control blood sugar in adults with type 1 and type 2 diabetes

By Team ABLE

Sanofi India has launched Toujeo, a new product for the management of diabetes. Toujeo is a once-daily, long-acting basal analog insulin that improves glycemic control in adults with type 1 and type 2 diabetes.

Low blood sugar, or hypoglycemia is a constant fear amongst people on insulin. Toujeo, according to Sanofi, has demonstrated that it effectively lowers blood glucose, while minimizing the risk of hypoglycemia.

It works by slowly releasing small amounts of insulin to provide continuous glucose-lowering activity that lasts beyond 24 hours. With its stable and flat/peak-less action profile, Toujeo reduces glycemic variability, i.e. the daily highs and lows that people with diabetes on insulin may experience.

Sanofi has said that the product also comes with an impressive MY COACH patient support program (offered free to patients prescribed Toujeo). This patient support program provides six comprehensive months of hand-holding patients through their treatment journey - tips on diet and lifestyle, training on injection techniques, sugar monitoring and more, via a mix of telephonic and in-person sessions.